Q4 2015 13F Holders as of 12/31/2015
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
14.4M
-
Number of holders
-
150
-
Total 13F shares, excl. options
-
13.2M
-
Shares change
-
-124K
-
Total reported value, excl. options
-
$475M
-
Value change
-
-$3.26M
-
Put/Call ratio
-
0.46
-
Number of buys
-
83
-
Number of sells
-
-53
-
Price
-
$38.16
Significant Holders of Anika Therapeutics, Inc. - Common Stock, par value $0.01 per share (ANIK) as of Q4 2015
162 filings reported holding ANIK - Anika Therapeutics, Inc. - Common Stock, par value $0.01 per share as of Q4 2015.
Anika Therapeutics, Inc. - Common Stock, par value $0.01 per share (ANIK) has 150 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 13.2M shares
of 14.4M outstanding shares and own 91.24% of the company stock.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (1.19M shares), THOMPSON SIEGEL & WALMSLEY LLC (977K shares), BlackRock Fund Advisors (953K shares), DIMENSIONAL FUND ADVISORS LP (775K shares), Kalos Management, Inc. (744K shares), VANGUARD GROUP INC (639K shares), BTIM Corp. (500K shares), Portolan Capital Management, LLC (489K shares), AMI ASSET MANAGEMENT CORP (391K shares), and BlackRock Institutional Trust Company, N.A. (381K shares).
This table shows the top 150 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.